For cases lacking typical driver mutations, translocations involving PDGFRA/B, FGFR1 and JAK2, and potentially AML-type alterations, should be investigated in addition to mutations found in myeloid neoplasms (MN) in general. This evidence concerns the gene JAK2 and myeloid neoplasm.